JP2016534142A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534142A5
JP2016534142A5 JP2016542408A JP2016542408A JP2016534142A5 JP 2016534142 A5 JP2016534142 A5 JP 2016534142A5 JP 2016542408 A JP2016542408 A JP 2016542408A JP 2016542408 A JP2016542408 A JP 2016542408A JP 2016534142 A5 JP2016534142 A5 JP 2016534142A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition
composition according
cps
mometasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016542408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534142A (ja
JP6203967B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/064251 external-priority patent/WO2015036902A1/en
Publication of JP2016534142A publication Critical patent/JP2016534142A/ja
Publication of JP2016534142A5 publication Critical patent/JP2016534142A5/ja
Application granted granted Critical
Publication of JP6203967B2 publication Critical patent/JP6203967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016542408A 2013-09-13 2014-09-04 モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物 Active JP6203967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2975MU2013 2013-09-13
IN2975/MUM/2013 2013-09-13
PCT/IB2014/064251 WO2015036902A1 (en) 2013-09-13 2014-09-04 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017165305A Division JP6664358B2 (ja) 2013-09-13 2017-08-30 モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物

Publications (3)

Publication Number Publication Date
JP2016534142A JP2016534142A (ja) 2016-11-04
JP2016534142A5 true JP2016534142A5 (enExample) 2017-02-23
JP6203967B2 JP6203967B2 (ja) 2017-09-27

Family

ID=51688369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016542408A Active JP6203967B2 (ja) 2013-09-13 2014-09-04 モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物
JP2017165305A Active JP6664358B2 (ja) 2013-09-13 2017-08-30 モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017165305A Active JP6664358B2 (ja) 2013-09-13 2017-08-30 モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物

Country Status (23)

Country Link
US (1) US9078923B2 (enExample)
EP (2) EP3043773B1 (enExample)
JP (2) JP6203967B2 (enExample)
BR (1) BR112015018252B1 (enExample)
CY (1) CY1124675T1 (enExample)
DK (1) DK3043773T3 (enExample)
ES (1) ES2891729T3 (enExample)
FR (1) FR21C1057I2 (enExample)
HR (1) HRP20211515T1 (enExample)
HU (1) HUE056448T2 (enExample)
LT (1) LT3043773T (enExample)
MX (1) MX367674B (enExample)
MY (1) MY191380A (enExample)
NL (1) NL301154I2 (enExample)
NO (1) NO2021045I1 (enExample)
PH (1) PH12016500433B1 (enExample)
PL (1) PL3043773T3 (enExample)
PT (1) PT3043773T (enExample)
RS (1) RS62383B1 (enExample)
SI (1) SI3043773T1 (enExample)
SM (1) SMT202100563T1 (enExample)
UA (1) UA116793C2 (enExample)
WO (1) WO2015036902A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6203967B2 (ja) * 2013-09-13 2017-09-27 グレンマーク・スペシャルティー・エスエー モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) * 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
RU2686670C2 (ru) 2013-10-04 2019-04-30 Гленмарк Спешиалити С.А. Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2016155021A1 (zh) 2015-04-03 2016-10-06 绿仕科技控股有限公司 环境控制系统
EP3468532B1 (en) * 2017-06-28 2020-09-23 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
TWI790316B (zh) * 2017-12-14 2023-01-21 瑞士商葛蘭馬克專業股份公司 用於向人類經鼻投與之含有水性醫藥組合物的分配裝置
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2020070599A1 (en) * 2018-10-05 2020-04-09 Glenmark Specialty S.A. Nebulization composition of mometasone
CN109602693A (zh) * 2018-11-13 2019-04-12 华润三九(南昌)药业有限公司 糠酸莫米松凝胶及其制备方法
TW202133860A (zh) * 2019-12-06 2021-09-16 日商東興藥品工業股份有限公司 含有類固醇化合物及歐羅派特錠的醫藥組成物
CA3181959A1 (en) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
PE20251774A1 (es) * 2023-11-21 2025-07-14 Glenmark Specialty Sa Composicion de aerosol nasal
WO2025137749A1 (pt) * 2023-12-27 2025-07-03 Eurofarma Laboratórios S.A. Processo de solubilização de olopatadina e seu uso

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
WO2001026658A2 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
MXPA05005044A (es) * 2002-11-12 2005-07-01 Alcon Inc El uso de un agente antialergico y un esteroide para tratar rinitis alergica.
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2586553C (en) 2004-11-24 2015-02-10 Alcon, Inc. Nasal sprayer containing a formulation with olopatadine
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
CA2631757A1 (en) * 2005-12-02 2007-06-07 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
AR059358A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
AU2007311607A1 (en) 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
AR073796A1 (es) * 2008-10-10 2010-12-01 Schering Corp Formulaciones de corticosteroides y sus metodos de tratamiento
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
KR101261230B1 (ko) * 2010-11-29 2013-05-07 한림제약(주) 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
ES2626134T3 (es) * 2011-01-04 2017-07-24 Bausch & Lomb Incorporated Composiciones de bepotastina
FR2970180B1 (fr) 2011-01-06 2013-08-02 Substipharm Dev Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
JP6203967B2 (ja) * 2013-09-13 2017-09-27 グレンマーク・スペシャルティー・エスエー モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物

Similar Documents

Publication Publication Date Title
JP2016534142A5 (enExample)
JP2016535777A5 (enExample)
JP2011201907A5 (enExample)
HRP20211515T1 (hr) Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni
JP2020007356A5 (enExample)
JP2016512494A5 (enExample)
JP2016534153A5 (enExample)
FI3435996T3 (fi) Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa
SI3193835T1 (en) Liquid inhalation preparation containing rpl554
JP2015512406A5 (enExample)
JP2011513492A5 (enExample)
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
JP2015519356A5 (enExample)
JP2013513612A5 (enExample)
RU2013104401A (ru) Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
HRP20220929T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje astme
JP2018529742A5 (enExample)
JP2012520882A5 (enExample)
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
CN107405404A (zh) 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
JP2017105859A5 (enExample)
JP2017105862A5 (enExample)
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
JP2019182878A5 (enExample)
HRP20221185T1 (hr) Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom